The Patent Finder

Terms ending in 2044

AstraZeneca AB

Every in-force patent on AstraZeneca AB's record whose computed term ends in 2044, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,178,876Conjugates Comprising Cleavable Linkers
In force
 · High confidence
AstraZeneca ABIn forceHigh confidence
US 12,337,038Conjugates Comprising Cleavable Beta-Glucuronide-Containing Linkers
In force
 · High confidence
AstraZeneca ABIn forceHigh confidence
US 12,758,555Pharmaceutical Formulations
In force
 · High confidence
AstraZeneca ABIn forceHigh confidence
US 12,686,707ANTI-STEAP2 Chimeric Antigen Receptors and Uses Thereof
In force
 · High confidence
Medlmmune, LLCIn forceHigh confidence
US 12,698,282Inhibitors of Myeloperoxidase
In force
 · High confidence
AstraZeneca ABIn forceHigh confidence
US 12,747,223N-(2-(3-Cyano-2-Azabicyclo[31.0]HEXAN-2-YL)-2-Oxoethyl)QUINOLINE-4-Carboxamides
In force
 · High confidence
AstraZeneca ABIn forceHigh confidence
US 12,653,828Polq Inhibitors
In force
 · High confidence
AstraZeneca ABIn forceHigh confidence
7 of 7 patents shown. Soonest term end first, then patent number.
6 of these are in force and held by AstraZeneca AB.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited